ID   GT9
AC   CVCL_IR53
DR   IARC_TP53; 4530
DR   Wikidata; Q54871833
RX   Patent=WO1995007105A1;
RX   PubMed=7757303;
CC   Group: Patented cell line.
CC   Doubling time: 36 hours (PubMed=7757303).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249_Pro250delinsSerAla (c.747_748delGCinsTG); Zygosity=Homozygous (PubMed=7757303).
CC   Derived from site: In situ; Brain, right temporal lobe; UBERON=UBERON_0002809.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 29-06-23; Version: 9
//
RX   Patent=WO1995007105A1;
RA   Sobol R.E., Royston I., Fakhrai H.;
RT   "Haplotype-matched cytokine-secreting cells and methods of using to
RT   stimulate an immune response.";
RL   Patent number WO1995007105A1, 16-Mar-1995.
//
RX   PubMed=7757303; DOI=10.1007/BF02639435;
RA   Gjerset R.A., Fakhrai H., Shawler D.L., Turla S., Dorigo O.,
RA   Grover-Bardwick A., Mercola D., Wen S.-F., Collins H., Lin H.,
RA   Varella-Garcia M., Kruse C.A., Royston I., Sobol R.E.;
RT   "Characterization of a new human glioblastoma cell line that expresses
RT   mutant p53 and lacks activation of the PDGF pathway.";
RL   In Vitro Cell. Dev. Biol. Anim. 31:207-214(1995).
//